The tweet was deleted by the author.
But we saved everything 🙂.
Corbus Pharmaceuticals Holdings, Inc. will deliver a corporate overview and engage with investors at two influential healthcare conferences.
The company is set to participate in the RBC Capital Markets Global Healthcare Conference from May 19 to 20 and the Jefferies Global Healthcare Conference from June 2 to 4. These events provide an opportunity for Corbus Pharmaceuticals Holdings, Inc. to outline its latest developments, strategic outlook, and engage directly with industry stakeholders and investors. Further details can be found on the company’s official channels.
The company recently marked a milestone in its CRB-913 obesity study, initiating last patient first visit in the CANYON-1 trial with 240 participants. Corbus is also preparing to present updated Phase 1/2 results for CRB-701 at the 2026 ASCO annual meeting. Both programs remain in focus as the company updates investors at upcoming conferences.